Cardurion Pharmaceuticals, Inc is a pioneering cardiovascular company based in Burlington, MA. With a team of experienced experts and industry veterans, they are dedicated to developing groundbreaking therapeutics for patients with cardiovascular disease. Their strategic portfolio approach, in-house drug discovery, and strong partnerships position them for rapid growth and innovation in the field.
Cardurion Pharmaceuticals is at the forefront of cardiovascular research, focusing on inhibiting PDE9 and CaMKII to address unmet needs in heart failure, arrhythmias, and other cardiovascular diseases. With their upcoming clinical programs and pipeline expansion in 2022, they aim to deliver next-generation treatments and improve patient outcomes in multiple indications.
Generated from the website